Literature DB >> 26299960

Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs.

Amy L Firth1, Tushar Menon1, Gregory S Parker1, Susan J Qualls1, Benjamin M Lewis1, Eugene Ke1, Carl T Dargitz1, Rebecca Wright1, Ajai Khanna2, Fred H Gage1, Inder M Verma3.   

Abstract

Lung disease is a major cause of death in the United States, with current therapeutic approaches serving only to manage symptoms. The most common chronic and life-threatening genetic disease of the lung is cystic fibrosis (CF) caused by mutations in the cystic fibrosis transmembrane regulator (CFTR). We have generated induced pluripotent stem cells (iPSCs) from CF patients carrying a homozygous deletion of F508 in the CFTR gene, which results in defective processing of CFTR to the cell membrane. This mutation was precisely corrected using CRISPR to target corrective sequences to the endogenous CFTR genomic locus, in combination with a completely excisable selection system, which significantly improved the efficiency of this correction. The corrected iPSCs were subsequently differentiated to mature airway epithelial cells where recovery of normal CFTR expression and function was demonstrated. This isogenic iPSC-based model system for CF could be adapted for the development of new therapeutic approaches.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26299960      PMCID: PMC4559351          DOI: 10.1016/j.celrep.2015.07.062

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  24 in total

Review 1.  RNA-guided genetic silencing systems in bacteria and archaea.

Authors:  Blake Wiedenheft; Samuel H Sternberg; Jennifer A Doudna
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 2.  Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment.

Authors:  Mark P Rogan; David A Stoltz; Douglas B Hornick
Journal:  Chest       Date:  2011-06       Impact factor: 9.410

3.  Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis.

Authors:  Xingshen Sun; Hongshu Sui; John T Fisher; Ziying Yan; Xiaoming Liu; Hyung-Ju Cho; Nam Soo Joo; Yulong Zhang; Weihong Zhou; Yaling Yi; Joann M Kinyon; Diana C Lei-Butters; Michelle A Griffin; Paul Naumann; Meihui Luo; Jill Ascher; Kai Wang; Timothy Frana; Jeffrey J Wine; David K Meyerholz; John F Engelhardt
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

4.  Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs.

Authors:  Caryn R Hale; Sonali Majumdar; Joshua Elmore; Neil Pfister; Mark Compton; Sara Olson; Alissa M Resch; Claiborne V C Glover; Brenton R Graveley; Rebecca M Terns; Michael P Terns
Journal:  Mol Cell       Date:  2012-01-05       Impact factor: 17.970

5.  Development of a porcine model of cystic fibrosis.

Authors:  Michael J Welsh; Christopher S Rogers; David A Stoltz; David K Meyerholz; Randall S Prather
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

6.  Induction of pluripotent stem cells from fibroblast cultures.

Authors:  Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Shinya Yamanaka
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

7.  Alteration of CFTR transmembrane span integration by disease-causing mutations.

Authors:  Anna E Patrick; Andrey L Karamyshev; Linda Millen; Philip J Thomas
Journal:  Mol Biol Cell       Date:  2011-10-12       Impact factor: 4.138

8.  Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.

Authors:  Ana M Crane; Philipp Kramer; Jacquelin H Bui; Wook Joon Chung; Xuan Shirley Li; Manuel L Gonzalez-Garay; Finn Hawkins; Wei Liao; Daniela Mora; Sangbum Choi; Jianbin Wang; Helena C Sun; David E Paschon; Dmitry Y Guschin; Philip D Gregory; Darrell N Kotton; Michael C Holmes; Eric J Sorscher; Brian R Davis
Journal:  Stem Cell Reports       Date:  2015-03-12       Impact factor: 7.765

9.  Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs.

Authors:  Christopher S Rogers; David A Stoltz; David K Meyerholz; Lynda S Ostedgaard; Tatiana Rokhlina; Peter J Taft; Mark P Rogan; Alejandro A Pezzulo; Philip H Karp; Omar A Itani; Amanda C Kabel; Christine L Wohlford-Lenane; Greg J Davis; Robert A Hanfland; Tony L Smith; Melissa Samuel; David Wax; Clifton N Murphy; August Rieke; Kristin Whitworth; Aliye Uc; Timothy D Starner; Kim A Brogden; Joel Shilyansky; Paul B McCray; Joseph Zabner; Randall S Prather; Michael J Welsh
Journal:  Science       Date:  2008-09-26       Impact factor: 47.728

10.  Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.

Authors:  Noemi Fusaki; Hiroshi Ban; Akiyo Nishiyama; Koichi Saeki; Mamoru Hasegawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2009       Impact factor: 3.493

View more
  103 in total

Review 1.  Tissue Engineering and Regenerative Medicine 2015: A Year in Review.

Authors:  Holly Wobma; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part B Rev       Date:  2016-02-23       Impact factor: 6.389

Review 2.  Gene-targeting pharmaceuticals for single-gene disorders.

Authors:  Arthur L Beaudet; Linyan Meng
Journal:  Hum Mol Genet       Date:  2015-11-30       Impact factor: 6.150

Review 3.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

Review 4.  In Vitro Models to Study Human Lung Development, Disease and Homeostasis.

Authors:  Alyssa J Miller; Jason R Spence
Journal:  Physiology (Bethesda)       Date:  2017-05

Review 5.  Genome editing: a robust technology for human stem cells.

Authors:  Arun Pandian Chandrasekaran; Minjung Song; Suresh Ramakrishna
Journal:  Cell Mol Life Sci       Date:  2017-04-12       Impact factor: 9.261

Review 6.  Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System.

Authors:  Daniel Mendes Filho; Patrícia de Carvalho Ribeiro; Lucas Felipe Oliveira; Ana Luiza Romero Terra Dos Santos; Ricardo Cambraia Parreira; Mauro Cunha Xavier Pinto; Rodrigo Ribeiro Resende
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

Review 7.  Stem cell-derived organoids and their application for medical research and patient treatment.

Authors:  Sina Bartfeld; Hans Clevers
Journal:  J Mol Med (Berl)       Date:  2017-04-08       Impact factor: 4.599

Review 8.  What rheumatologists need to know about CRISPR/Cas9.

Authors:  Gary J Gibson; Maozhou Yang
Journal:  Nat Rev Rheumatol       Date:  2017-02-09       Impact factor: 20.543

9.  CRISPR-Cas9 gene editing causes alternative splicing of the targeting mRNA.

Authors:  Qian Zhang; Yao Fu; Chitra Thakur; Zhuoyue Bi; Priya Wadgaonkar; Yiran Qiu; Liping Xu; M'Kya Rice; Wenxuan Zhang; Bandar Almutairy; Fei Chen
Journal:  Biochem Biophys Res Commun       Date:  2020-05-24       Impact factor: 3.575

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.